Drug therapies for the primary prevention of cardiovascular events: trials and errors: 2009 Ancel Keys Memorial Lecture.
作者信息
Psaty Bruce M
机构信息
Cardiovascular Health Research Unit, 1730 Minor Ave, Suite 1360, Seattle, WA 98101, USA.
出版信息
Circulation. 2010 Feb 23;121(7):940-5. doi: 10.1161/CIRCULATIONAHA.109.933705.
Abstract
摘要
相似文献
1
Drug therapies for the primary prevention of cardiovascular events: trials and errors: 2009 Ancel Keys Memorial Lecture.心血管事件一级预防的药物治疗：试验与失误：2009年安塞尔·基斯纪念讲座
Circulation. 2010 Feb 23;121(7):940-5. doi: 10.1161/CIRCULATIONAHA.109.933705.
2
A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.一项比较噻唑烷二酮类药物对心血管危险因素影响的荟萃分析。
Arch Intern Med. 2004 Oct 25;164(19):2097-104. doi: 10.1001/archinte.164.19.2097.
3
Ancel Keys Lecture. The three beauties. Bench, clinical, and population research.安塞尔·基斯讲座。三位佳人。实验台研究、临床研究和群体研究。
Circulation. 1992 Oct;86(4):1323-31. doi: 10.1161/01.cir.86.4.1323.
4
The safety of rosiglitazone in the treatment of type 2 diabetes.罗格列酮治疗2型糖尿病的安全性。
Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579.
5
[The best of epidemiology and cardiovascular prevention in 2006].《2006年流行病学与心血管疾病预防的最佳实践》
Arch Mal Coeur Vaiss. 2007 Jan;100 Spec No 1:57-64.
6
[Therapy with glitazones--a risk for cardiovascular disease?].噻唑烷二酮类药物治疗——心血管疾病的一个风险？
Dtsch Med Wochenschr. 2007 Dec;132(49):2629-32. doi: 10.1055/s-2007-993110.
7
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.罗格列酮与心血管事件的长期风险：一项荟萃分析。
JAMA. 2007 Sep 12;298(10):1189-95. doi: 10.1001/jama.298.10.1189.
8
Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.罗格列酮和吡格列酮对2型糖尿病患者心血管风险的影响。
Pharmacotherapy. 2006 Feb;26(2):168-81. doi: 10.1592/phco.26.2.168.
9
Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing?对于吡格列酮类药物的心血管风险或危害的临床试验证据是否有足够说服力？
Curr Diab Rep. 2009 Oct;9(5):342-7. doi: 10.1007/s11892-009-0054-1.
10
[An overweight diabetic does not tolerate metformin. Insulin sensitizer can be prescribed alone, too].超重的糖尿病患者不耐受二甲双胍。也可单独开具胰岛素增敏剂。
MMW Fortschr Med. 2003 Dec 4;145(49):58.
引用本文的文献
1
Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy.接受抑制性抗逆转录病毒治疗的HIV感染者按年龄划分的已判定发病和死亡结局。
PLoS One. 2014 Apr 11;9(4):e95061. doi: 10.1371/journal.pone.0095061. eCollection 2014.
2
The contribution of a 9p21.3 variant, a KIF6 variant, and C-reactive protein to predicting risk of myocardial infarction in a prospective study.在一项前瞻性研究中，9p21.3 变异、KIF6 变异和 C 反应蛋白对预测心肌梗死风险的贡献。
BMC Cardiovasc Disord. 2011 Mar 15;11:10. doi: 10.1186/1471-2261-11-10.
3
Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study.他汀类药物治疗者的心血管事件：3 年记录链接研究中治疗依从性的影响。
Eur J Clin Pharmacol. 2011 Apr;67(4):407-414. doi: 10.1007/s00228-010-0958-3. Epub 2010 Dec 9.
本文引用的文献
1
Preliminary observations from preliminary trial results: have we finally had enough?初步试验结果的初步观察：我们最终是否已获取足够信息？
Circ Cardiovasc Qual Outcomes. 2008 Sep;1(1):54-7. doi: 10.1161/CIRCOUTCOMES.108.811901.
2
Unintended hepatic adverse events associated with cancer chemotherapy.与癌症化疗相关的意外肝脏不良事件。
Toxicol Pathol. 2010 Jan;38(1):142-7. doi: 10.1177/0192623309351719. Epub 2009 Oct 26.
3
Variation in event rates in trials of patients with type 2 diabetes.2型糖尿病患者试验中事件发生率的差异。
JAMA. 2009 Oct 21;302(15):1698-700. doi: 10.1001/jama.2009.1497.
4
C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force.C反应蛋白作为冠心病的一个危险因素：美国预防服务工作组的系统评价和荟萃分析
Ann Intern Med. 2009 Oct 6;151(7):483-95. doi: 10.7326/0003-4819-151-7-200910060-00009.
5
Case series of liver failure associated with rosiglitazone and pioglitazone.与罗格列酮和吡格列酮相关的肝衰竭病例系列。
Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1238-43. doi: 10.1002/pds.1804.
6
Systematic review: glucose control and cardiovascular disease in type 2 diabetes.系统评价：2型糖尿病患者的血糖控制与心血管疾病
Ann Intern Med. 2009 Sep 15;151(6):394-403. doi: 10.7326/0003-4819-151-6-200909150-00137. Epub 2009 Jul 20.
7
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials.他汀类药物对无心血管疾病但有心血管危险因素人群的益处：随机对照试验的荟萃分析。
BMJ. 2009 Jun 30;338:b2376. doi: 10.1136/bmj.b2376.
8
Predicting the 30-year risk of cardiovascular disease: the framingham heart study.预测心血管疾病的30年风险：弗雷明汉心脏研究
Circulation. 2009 Jun 23;119(24):3078-84. doi: 10.1161/CIRCULATIONAHA.108.816694. Epub 2009 Jun 8.
9
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.罗格列酮用于2型糖尿病口服联合治疗的心血管结局评估（RECORD）：一项多中心、随机、开放标签试验
Lancet. 2009 Jun 20;373(9681):2125-35. doi: 10.1016/S0140-6736(09)60953-3. Epub 2009 Jun 6.
10
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.一种复方制剂（Polycap）对无心血管疾病中年个体危险因素的影响（TIPS）：一项II期双盲随机试验。
Lancet. 2009 Apr 18;373(9672):1341-51. doi: 10.1016/S0140-6736(09)60611-5. Epub 2009 Mar 30.
Zotero 插件